{Reference Type}: Case Reports
{Title}: Everolimus-Related Chylothorax: A Rare Case Report.
{Author}: Yazdalı Köylü N;Koç NS;Sancar EN;Sarınç S;Altun B;
{Journal}: Exp Clin Transplant
{Volume}: 22
{Issue}: 6
{Year}: 2024 Jun
{Factor}: 0.938
{DOI}: 10.6002/ect.2023.0252
{Abstract}: Everolimus is an orally administered mechanistic target of rapamycin inhibitor in solid-organ transplant patients. In addition to the common adverse side effects of this treatment, such as hyperlipidemia, rash, stomatitis, anorexia, diarrhea, anemia, thrombocytopenia, and leukopenia, pulmonary toxicity is also an important adverse side effect. Although pulmonary toxicity due to everolimus has been reported mostly as pneumonitis, cases of pleural effusion due to everolimus have also been reported rarely. Chylothorax is defined as the accumulation of lymphatic fluid in the pleural space. It may develop secondary to trauma or malignancy. In this case report, we present a patient with chylothorax after everolimus treatment.